Overexpression of sphingosine-1 phosphate lyase protects insulin-secreting cells against cytokine toxicity [Metabolism]

Increasing evidence suggests a crucial role of inflammation in cytokine-mediated β-cell dysfunction and death in type-1 diabetes (T1DM), though the mechanisms are incompletely understood. Sphingosine-1 phosphate (S1P) is a multifunctional bioactive sphingolipid involved in the development of many autoimmune and inflammatory diseases. Here, we investigated the role of intracellular S1P in insulin-secreting INS1E cells by genetically manipulating the S1P-metabolizing enzyme S1P lyase (SPL). The expression of SPL was downregulated by cytokines in INS1E cells and rat islets. Overexpression of SPL protected against cytokine toxicity. Interestingly, the SPL overexpression did not suppress the cytokine-induced NFκB-iNOS-NO pathway, but attenuated calcium leakage from endoplasmic reticulum (ER) stores as manifested by lower cytosolic calcium levels, higher expression of the ER-protein Sec61a, decreased dephosphorylation of Bcl-2-associated death promoter (BAD) protein and weaker caspase-3 activation in cytokine-treated (IL-1β, TNFα and IFNγ) cells. This coincided with reduced cytokine-mediated ER stress, indicated by measurements of CCAAT-enhancer-binding protein homologous protein (CHOP) and immunoglobulin heavy chain binding protein (BIP) level. Moreover, cytokine-treated SPL-overexpressing cells exhibited increased expression of prohibitin 2 (PHB2), involved in the regulation of mitochondrial assembly and respiration. SPL-overexpressing cells were partially protected against cytokine-mediated ATP reduction and inhibition of glucose-induced insulin secretion. siRNA-mediated SPL suppression resulted in effects opposite to those observed for SPL overexpression. Knock-down of PHB2 partially reversed beneficial effects of SPL overexpression. In conclusion, the relatively low endogenous SPL expression level in insulin-secreting cells contributes to their extraordinary vulnerability to proinflammatory cytokine toxicity and may therefore represent a promising target for β-cell protection in T1DM.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h9E2Ku
via IFTTT